KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Income from Continuing Operations (2017 - 2025)

Bionano Genomics' Income from Continuing Operations history spans 7 years, with the latest figure at 8502000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 80.78% year-over-year to 8502000.0; the TTM value through Sep 2025 reached 38587000.0, up 71.58%, while the annual FY2024 figure was 112017000.0, 51.82% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 8502000.0 at Bionano Genomics, down from 6858000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3102000.0 in Q1 2025 and bottomed at 112566000.0 in Q3 2023.
  • The 5-year median for Income from Continuing Operations is 29952000.0 (2022), against an average of 29894894.74.
  • The largest annual shift saw Income from Continuing Operations plummeted 253.88% in 2023 before it soared 90.13% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 22949000.0 in 2021, then crashed by 68.53% to 38677000.0 in 2022, then decreased by 13.48% to 43891000.0 in 2023, then soared by 54.15% to 20125000.0 in 2024, then surged by 57.75% to 8502000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Income from Continuing Operations are 8502000.0 (Q3 2025), 6858000.0 (Q2 2025), and 3102000.0 (Q1 2025).